Monoclonal antibodyPhase 3 trialInvestigational
Dinutuximab beta
How it works
Blocks the GD2 protein on cancer cells, helping the immune system recognize and attack them.
Cancer types
Colorectal Cancer— All patients
Efficacy
In clinical trials, dinutuximab beta improved response rates and overall survival in patients with metastatic colorectal cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.